BenzingaSeptember 9, 2026 at 10:21 AM NYLast Month
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
